2217 related articles for article (PubMed ID: 33980688)
1. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
2. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
Front Immunol; 2021; 12():683800. PubMed ID: 34248968
[TBL] [Abstract][Full Text] [Related]
4. Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way.
Cao Z; Wang J; Liu X; Liu Y; Li F; Liu M; Chiu S; Jin X
mBio; 2024 Jun; 15(6):e0090524. PubMed ID: 38727220
[TBL] [Abstract][Full Text] [Related]
5. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.
Aboudounya MM; Heads RJ
Mediators Inflamm; 2021; 2021():8874339. PubMed ID: 33505220
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
8. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
[TBL] [Abstract][Full Text] [Related]
9. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
11. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
15. The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner.
Callahan V; Hawks S; Crawford MA; Lehman CW; Morrison HA; Ivester HM; Akhrymuk I; Boghdeh N; Flor R; Finkielstein CV; Allen IC; Weger-Lucarelli J; Duggal N; Hughes MA; Kehn-Hall K
Viruses; 2021 Jun; 13(6):. PubMed ID: 34205098
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19.
Wang YC; Tsai CH; Wang YC; Yen LC; Chang YW; Sun JR; Lin TY; Chiu CH; Chao YC; Chang FY
Infection; 2024 Jun; 52(3):955-983. PubMed ID: 38133713
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
Paidi RK; Jana M; Mishra RK; Dutta D; Pahan K
J Immunol; 2021 Nov; 207(10):2521-2533. PubMed ID: 34645689
[TBL] [Abstract][Full Text] [Related]
18. The COVID-19 pandemic: a global health crisis.
Pollard CA; Morran MP; Nestor-Kalinoski AL
Physiol Genomics; 2020 Nov; 52(11):549-557. PubMed ID: 32991251
[TBL] [Abstract][Full Text] [Related]
19. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
Khoshkam Z; Aftabi Y; Stenvinkel P; Paige Lawrence B; Rezaei MH; Ichihara G; Fereidouni S
J Adv Res; 2021 Jul; 31():49-60. PubMed ID: 33520309
[TBL] [Abstract][Full Text] [Related]
20. Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.
Wang C; Xie J; Zhao L; Fei X; Zhang H; Tan Y; Nie X; Zhou L; Liu Z; Ren Y; Yuan L; Zhang Y; Zhang J; Liang L; Chen X; Liu X; Wang P; Han X; Weng X; Chen Y; Yu T; Zhang X; Cai J; Chen R; Shi ZL; Bian XW
EBioMedicine; 2020 Jul; 57():102833. PubMed ID: 32574956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
